Concentration of E-cadherin Correlated with Pathologic Features in Gastric Cancer.
10.5230/jkgca.2004.4.3.156
- Author:
Hoon HUR
1
;
Gyo Young SONG
;
Jin Jo KIM
;
Hyung Min CHIN
;
Wook KIM
;
Cho Hyun PARK
;
Seung Man PARK
;
Keun Woo LIM
;
Woo Bae PARK
;
Seung Nam KIM
;
Hae Myoung JEON
Author Information
1. Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea. hmjeon@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
E-cadherin;
Gatric cancer;
Tumor marker
- MeSH:
Cadherins*;
Enzyme-Linked Immunosorbent Assay;
Humans;
Immunohistochemistry;
Lymph Nodes;
Neoplasm Metastasis;
Stomach Neoplasms*
- From:Journal of the Korean Gastric Cancer Association
2004;4(3):156-163
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: While E-cadherin in normal cells induces calcium-dependent cell-cell adhesion, in malignant cell, it plays a role in invasion and metastasis with a reduction of adhesion. Serum soluble E-cadherin is a result of the reduction of the cellular E-cadherin molecule and is found in the circulation of normal individuals, but it is particularly known to be increased in patients with malignancies. Accordingly, through checking the level of serum soluble E-cadherin in patients with gastric cancer and analyzing it in the view of clinicopathology, we investigated whether serum soluble E-cadherin could be translated into a clinicopathologic esult and used as a tumor marker. MATERIALS AND METHODS: The investigation targeted 88 patients who had been diagnosed as having gastric cancer by the Department of Surgery, St. Mary's Hospital, from October 1, 2002, to July 30, 2003, and who had under gone performed surgery. We measured the level of preoperative serum E-cadherin in the 88 patients by unsing ELISA. Among them, we collected gastric cancer tissues from 54 patients and executed immunohistochemistry for E-cadherin. The samples were compared with normal tissues in terms of both serum E-cadherin level and immunohistochemistry level, as well as with other clinicopathologic factors. RESULTS: The mean serum E-cadherin level of the 88 patients was 4368.7 ng/ml and was significantly higher than the level in 12 normal control patients, 3335.5 ng/ml (P=0.016). In terms of clinicopathology, the serum level of E-cadherin was significantly correlated with increasing age (P=0.0006) and was higher in positive venous invasion patients (P=0.0005). When the E-cadherin immunohistochemical stain was compared with the serum E-cadherin level in 54 patients, no significant statistically meaningful result was obtained (P=0.2881). However, 4 patients with serum E-cadherin levels about 6000 ng/ml were classified into the lower expression group (<80%) of E-cadherin immunohistochemicals stain. In the analysis for 36 patients who were early gastric cancer patients, the serum E-cadherin level in lymph-node-metastatic patients was higher than it was in the other patients (P=0.0442). CONCLUSION: The serum E-cadherin level in gastric cancer patients was higher than the level in normal control patients. In advanced gastric cancer patients, that the difference was increased. Also, since the E-cadherin level correlated with the serum E-cadherin level with venous invasion, it can be used as an effective tumor marker for gastric cancer. Particularly, in that the serum E-cadherin level correlated with lymph node metastasis in early gastic cancer, it can be used when a therapeutic method for early gastric cancer is selected.
